JP2024532619A5 - - Google Patents
Info
- Publication number
- JP2024532619A5 JP2024532619A5 JP2024537306A JP2024537306A JP2024532619A5 JP 2024532619 A5 JP2024532619 A5 JP 2024532619A5 JP 2024537306 A JP2024537306 A JP 2024537306A JP 2024537306 A JP2024537306 A JP 2024537306A JP 2024532619 A5 JP2024532619 A5 JP 2024532619A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- receptor antibody
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163238068P | 2021-08-27 | 2021-08-27 | |
| US63/238,068 | 2021-08-27 | ||
| US202263301012P | 2022-01-19 | 2022-01-19 | |
| US63/301,012 | 2022-01-19 | ||
| US202263333351P | 2022-04-21 | 2022-04-21 | |
| US63/333,351 | 2022-04-21 | ||
| PCT/US2022/075545 WO2023028606A1 (en) | 2021-08-27 | 2022-08-26 | Combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532619A JP2024532619A (ja) | 2024-09-05 |
| JP2024532619A5 true JP2024532619A5 (https=) | 2025-09-01 |
Family
ID=83897998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537306A Pending JP2024532619A (ja) | 2021-08-27 | 2022-08-26 | 併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325530A1 (https=) |
| EP (1) | EP4392137A1 (https=) |
| JP (1) | JP2024532619A (https=) |
| KR (1) | KR20240099142A (https=) |
| AU (1) | AU2022332306A1 (https=) |
| CA (1) | CA3229355A1 (https=) |
| IL (1) | IL310919A (https=) |
| MX (1) | MX2024002467A (https=) |
| TW (1) | TW202323296A (https=) |
| WO (1) | WO2023028606A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| TW202339798A (zh) * | 2022-01-19 | 2023-10-16 | 美商維紗妮絲生物公司 | Actrii抗體之治療 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| JP2025529933A (ja) | 2022-08-26 | 2025-09-09 | バーサニス・バイオ・インコーポレイテッド | ＡｃｔＲＩＩ抗体固定単位用量の治療 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025106773A1 (en) * | 2023-11-17 | 2025-05-22 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent |
| TW202535467A (zh) * | 2023-12-29 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗體－多肽偶聯物及其醫藥用途 |
| WO2025147483A1 (en) * | 2024-01-02 | 2025-07-10 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii chimeras |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
| WO2025217521A1 (en) * | 2024-04-12 | 2025-10-16 | Jnana Therapeutics Inc. | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist |
| WO2025247309A1 (zh) * | 2024-05-31 | 2025-12-04 | 上海齐鲁制药研究中心有限公司 | 融合蛋白分子及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| PT3565592T (pt) * | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
-
2022
- 2022-08-26 KR KR1020247010022A patent/KR20240099142A/ko active Pending
- 2022-08-26 JP JP2024537306A patent/JP2024532619A/ja active Pending
- 2022-08-26 CA CA3229355A patent/CA3229355A1/en active Pending
- 2022-08-26 IL IL310919A patent/IL310919A/en unknown
- 2022-08-26 TW TW111132340A patent/TW202323296A/zh unknown
- 2022-08-26 AU AU2022332306A patent/AU2022332306A1/en active Pending
- 2022-08-26 WO PCT/US2022/075545 patent/WO2023028606A1/en not_active Ceased
- 2022-08-26 EP EP22797198.3A patent/EP4392137A1/en active Pending
- 2022-08-26 MX MX2024002467A patent/MX2024002467A/es unknown
-
2024
- 2024-02-26 US US18/587,617 patent/US20240325530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532619A5 (https=) | ||
| JP7094327B2 (ja) | 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物 | |
| US20240325530A1 (en) | Combination therapies | |
| EP3398961B1 (en) | Triple activator activating glucagon, glp-1 and gip receptor | |
| US11135271B2 (en) | Glucagon derivatives with improved stability | |
| AU2023329487A1 (en) | Actrii antibody fixed unit dose treatments | |
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| CN121152634A (zh) | 用于治疗恶心和呕吐的方法和用途 | |
| WO2024027553A1 (zh) | 一种双功能融合蛋白及其用途 | |
| CN115212293A (zh) | 一种融合蛋白的制药用途 | |
| WO2025183966A1 (en) | Actrii antibodies with extended half life | |
| CN118488853A (zh) | 组合疗法 | |
| KR20250095833A (ko) | 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법 | |
| CA2972748C (en) | Glucagon derivatives with improved stability | |
| HK40094446A (zh) | Glp-1给药方案 | |
| HK40010066A (en) | Glucagon derivative | |
| WO2025259957A1 (en) | Compositions and methods for improving insulin sensitivity | |
| KR20180027924A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| HK40083623A (en) | Dosing regimen of glp-1 | |
| CA3162463A1 (en) | Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity | |
| TW202140061A (zh) | 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑 | |
| JP2023518645A (ja) | Ｇｌｐ－１の投薬レジメン | |
| BR112017014205B1 (pt) | Derivados de glucagon e seu uso, e uso de uma composição farmacêutica |